Fig. 2. Representative replots for the data collected in Fig. 1 after linearization.
a The similar potencies for olaparib vs. veliparib are readily apparent from the nearly identical slopes of the lines. In contrast, AZD-2461 is a less potent inhibitor of PARP1. b Comparison of the more potent inhibitors talazoparib and rucaparib vs. olaparib. Note the much steeper slopes and change in scale of the y-axis compared to (a). The data for olaparib in this plot are a duplicate from (a) to facilitate direct comparison. c The effect of HPF1 on inhibitor potency is readily seen for both olaparib and AZD-2461. The data for olaparib in this plot are a duplicate from (a) to facilitate direct comparison. A complete list of derived KI from these replots and multiple replicates are shown in Table 1.